Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes
Syndax Pharmaceuticals (NASDAQ: SNDX) said it entered private subscription agreements to issue $250.0 million of 2.25% Convertible Senior Notes due 2031, with an expected June 10, 2026 closing. Net proceeds are estimated at about $243 million for general corporate purposes. Notes pay semiannual interest, mature June 15, 2031, and have an initial conversion price of ~$24.76/share.
How this was made
The 30-second read
Why it matters
Key tradable elements are the $243M net proceeds, the ~35% conversion premium (~$24.76 initial conversion price), and the redemption/call constraints (no redemption before June 20, 2029; issuer redemption only if stock trades at ≥130% of conversion price for 20 days in a 30-day window).
Market read
Convertible financing can move the stock via dilution expectations and convertible hedging, while the premium and delayed redemption can moderate near-term pressure.
What to watch
Conversion is only mandatory upon certain circumstances; also, Syndax cannot redeem before June 20, 2029, which may reduce near-term call/dilution pressure versus standard structures.
Background
Syndax is a commercial-stage biopharma; the company is issuing convertible senior notes to raise net proceeds for working capital, R&D, commercialization, and business development.
Ticker impact
Syndax announced a $250M private placement of 2.25% convertible senior notes due 2031, including conversion premium and redemption terms.
Likely near-term volatility around the June 10 closing and any hedging/dilution expectations; direction depends on whether investors view proceeds as funding runway vs. dilution.
Convertible issuance with a ~35% conversion premium can be supportive if capital use is credible, but converts/dilution and potential hedging often pressure the stock, especially for commercial-stage biopharma.
Market effects
Adds another example of biotech using convertible debt to fund R&D/commercial spend, reinforcing the sector’s reliance on capital markets.
Primarily impacts US small/mid-cap biotech risk appetite and convertible-debt pricing sentiment.
Limited direct global spillover; mainly affects US equity and credit/convertible markets for similar issuers.
Counterpoint
If the market interprets the premium and terms as investor-friendly (and proceeds as de-risking pipeline/commercial execution), the overhang may be less severe than typical convertibles.
Key entities
- issuerSyndax Pharmaceuticals, Inc.
Subject of the private placement of $250M convertible senior notes due 2031.
- placement_agentJ. Wood Capital Advisors LLC
Sole placement agent for the private placement.
